The present invention is in the field of molecular hydrogen (H2) bio-production, particularly, the present invention provides genetically modified photosynthetic microalgae producing hydrogen in complete growth medium under ambient, continuous growth conditions at cost-effective amounts and to a process for hydrogen production using genetically modified photosynthetic microalga.
The present invention relates to a method of evaluating whether a subject already suffering from non-small cell lung carcinoma (NSCLC) will respond to a treatment of NSCLC, the treatment comprising immunotherapy, the method comprising determining a level of PD-L1 positive MVs in a test PB sample obtained from a subject suffering from NSCLC who has not yet been treated, followed by evaluating whether said subject will be a responder to a treatment of NSCLC comprising immunotherapy, if said level of PD-L1 positive MVs is increased relative to corresponding levels of PD-L1 positive MVs in control PB samples obtained from subjects also suffering from NSCLC, but being non-responders to said treatment of NSCLC comprising immunotherapy. Further, the present invention relates to a data processing system comprising a processor configured to perform the method of the invention.
The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an autotransporter comprising transmembrane linker and a trans- porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
The present Invention relates to a 5'-cap analog comprising a photcleavable coumarin group (PC-Cou) at a positively charged nitrogen of the N7-position of guanosine (I) or the N1-position of adenosine (II). The present invention further relates to a photodea vable nucleoside or nucleotide analog or salts thereof, comprising a photodeavable group at the N7-position of guanosine, at the N1-position of adenosine, or at the N3-position of cytidine.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (Germany)
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (Canada)
ISTITUTO SUPERIORE DI SANITÀ (Italy)
CONSIGLIO NAZIONALE DELLE RICERCHE (Italy)
IRBM S.P.A. (Italy)
Inventor
Martino, Gianvito
Panina, Paola
Nait-Oumesmar, Brahim
Baron-Van Evercooren, Anne
Kuhlmann, Tanja
Baranzini, Sergio
Goebels, Norbert
Zipp, Frauke
Hanuscheck, Nicholas
Antel, Jack
Agresti, Cristina
Abbracchio, Maria Pia
Eberini, Ivano
Parravicini, Chiara
Olla, Stefania
Bresciani, Alberto
Abstract
The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
6.
DIAGNOSIS, PROGNOSIS AND THERAPY OF NEUROINFLAMMATORY AUTOIMMUNE DISEASES USING CELLULAR AND SOLUBLE BLOOD PARAMETERS
The present invention relates to a method for determining distinguishing parameters of a neuro-inflammatory disease, said method comprising (a) obtaining parameters from a group of samples, wherein said group of samples comprises at least (i) a first subgroup of samples, and (ii) a second subgroup of samples, and (b) determining distinguishing parameters of the obtained parameters in step (a) at least between said first subgroup of samples and said second subgroup of samples by conducting analytical determination. Further, the present invention relates to a set of distinguishing parameters as well as distinct uses of such sets. Additionally, the present invention relates to a method for determining a subtype of a neuro-inflammatory autoimmune disease in a subject.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The invention relates to a device for multimodal analysis of sample material, e.g. from a tissue, which acquires molecule image data from the sample material in a spatially resolved fashion, e.g. using MALDI time-of-flight mass analyzer, records light-microscope image data from the sample material in a spatially resolved fashion and combines both with improved accuracy to form spatially resolved co-registered full image data.
The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
In various embodiments, a method for determining a neurological condition in a subject is provided. The method comprises: receiving motion signals which have been obtained from at least one body part on one side of the subject and from the corresponding body part on the other side of the subject; processing the motion signals to determine: i) a first group of parameters for each side of the subject based on predetermined magnitudes of the motion signals; ii) a second group of parameters for each side of the subject based on an analysis of noise component in the singular spectrum analysis of the motion signals; and iii) a third group of parameters for each side of the subject based on an analysis of periodic components of the motion signals; forming a vector, comprising the first group of parameters, the second group of parameters and the third group of parameters; comparing the formed vector to a plurality of reference vectors, wherein the reference vectors comprise at least one reference vector representing a healthy subject and at least one reference vector representing a subject that has been diagnosed with the neurological condition; and determining a probability for the subject having the neurological condition based on the outcome of the comparison.
The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Device for optically determining at least one property of a sample (2) positioned in or on a sample carrier (1) which can be moved relatively to the device, wherein the device is adapted to optically determine in a first step at least one property of a first sample (2) and at least one property of a second sample (2) without relative movement between the device and the sample carrier (1), wherein the sample carrier (1) is adapted to be moved so that in a second step a property of the second sample (2) can be optically determined, wherein the device is adapted to be tuned, depending on the information obtained with regard to the property of the second sample (2) determined in the first step, to optically determine the property of the second sample (2) in the second step, wherein a property of a third sample (2), not optically determined in the first step, is optically determined without relative movement between the device and the sample carrier (1) in the second step such that the device is adapted to be tuned, depending on the information obtained with regard to the property of the third sample (2) determined in the second step, to optically determine the property of the third sample (2) in a third step.
An optical matrix multiplication unit for an optoelectronic system can be used to form an artificial neural network, having N input waveguides, M output waveguides and a plurality of matrix multiplication unit cells for signal processing of optical signals of one each of the N input waveguides and for transferring the processed signals into one each of the M output waveguides, wherein each of the matrix multiplication unit cells is allocated to one of the input waveguides and one of the output waveguides and undertakes a unique allocation between said two allocated waveguides. Each of the matrix multiplication unit cells has, for signal processing and signal transfer, a directional coupler, having an electrooptical modulator for transmission control of the directional coupler, interconnected between the allocated input waveguide and the allocated output waveguide.
The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.
The invention relates to a compound nitarsone, or salt thereof for use in the treatment of a neurodegenerative disease, such as Alzheimer's disease (AD), dementia, Parkinson's disease (RD) or amyotrophic lateral sclerosis (ALS). The invention further relates to a pharmaceutical composition comprising said compound, or salt thereof for use in the treatment of a neurodegenerative disease.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
16.
DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73)
The present invention relates to radio- and fluorescence-labeled compounds, as well as their use as Diagnostics for Detecting Ecto-5'-Nucleotidase (CD73). The invention is further directed to a pharmaceutical composition comprising said compounds as well as to the compounds and the pharmaceutical composition for use in a method of diagnosis of a disease associated with increased or decreased CD73-expression as well as in the treatment of a disease associated with increased CD73-expression.
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
17.
Module for generating an interference pattern for producing a digital holographic image, a related method, and a digital holographic microscope
In various embodiments a module for generating an interference pattern for producing a digital holographic image is provided. The module comprises an adaptive lens arrangement configured to receive, from a microscope, an object wave of an intermediate image of a sample to be examined, and to generate an adapted object wave of the intermediate image of the sample by reducing a curvature of the object wave of the intermediate image; a reference input interface configured to receive an optical fiber delivering a reference wave from the coherent light source to the module and an interference arrangement configured to generate an interference pattern to be received by an imaging sensor arrangement, wherein the interference pattern is based on the adapted object wave and the reference wave from a coherent light source; wherein a position of the reference input interface of the module is configured to be adjustable with respect to at least two directions (x-y), wherein at least one of the adjustable directions is in parallel to a propagation direction of the reference wave leaving the optical fiber.
G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
G03H 1/04 - Processes or apparatus for producing holograms
18.
METHOD FOR EXPRESSION OF A TRANSGENE OF INTEREST FROM NEURAL PRECURSOR CELLS
The present invention relates to a method for expression of a transgene of interest from neural precursor cells (NPCs) comprising the steps of: a) Providing neural precursor cells; b1) i) targeted insertion of a nucleotide sequence encoding a transcriptional regulator protein being under the control of a suitable promoter into a first genomic location; and ii) targeted insertion of a nucleotide sequence encoding a transgene of interest into a second genomic location, wherein the transgene of interest is operably linked to a suitable promoter, which is regulated by the transcriptional regulator protein; or b2) targeted insertion of the nucleotide sequence encoding a transgene of interest into a genomic location, wherein the transgene of interest is operably linked to a constitutive promoter, and c) expression of the transgene of interest. Further is provided a system for expression of a transgene of interest from neural precursor cells.
The invention relates to anti-inflammatory agents, processes for their preparation, medicaments containing these agents and the use of these agents for the preparation of medicaments.
The present invention relates to an implant having a surface comprising a coating on at least a portion of the surface of the implant, wherein the coating comprises a first layer, the first layer comprising a polylactide and silver ions. The present Invention further relates to a method of manufacturing the implant as well as to an implant obtainable by that method.
The present invention relates to chitosan oligomers obtainable by enzymatic hydrolysis of chitosan polymers, compositions containing them, and uses thereof.
The present invention relates to p38 inhibitors for use in a method for the treatment of a coronavirus infection and/or the treatment or prevention of COVID-19 cytokine storm. Also provided are compositions comprising such inhibitors for use in the treatment of a corona virus infection, such as COVID-19.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
The present invention relates to a 5'-cap analog according to formula (I) or salts thereof, wherein the 5'-cap analog comprises a photocleavable group fused via a carbamate moiety to the 5'-cap structure.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 1/00 - Processes for the preparation of sugar derivatives
The present invention relates to a method for isolating extracellular vesicles (EVs) from a sample, comprising the step of contacting the sample with a supported lipid membrane (SLM) capable of binding the EVs.
The present invention relates to a method of generating a nanoparticle comprising contacting (a) a fusion protein (A), said fusion protein (A) comprising an antibody (A1) and a positively charged polypeptide (A2); (b) a positively charged polypeptide (B); and (c) a negatively charged molecule (C); thereby forming a nanoparticle. The present invention also relates to a nanoparticle obtainable by a method of the invention, as well as to a nanoparticle comprising (a) a fusion protein (A), said fusion protein (A) comprising an antibody (A1) and a positively charged polypeptide (A2); (b) a positively charged polypeptide (B); and (c) one or more negatively charged molecule(s) (C). The present invention also relates to a composition comprising a nanoparticle of the invention and to a nanoparticle or composition of the invention for use in therapy.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
26.
CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS
The present invention relates to a method of stratifying a subject with neurological or psychiatric disease manifestation, preferably with neuro-inflammatory autoimmune diseases a) determining i) a level of B cells in a test cerebrospinal fluid (CSF) sample obtained from a subject; ii) a level of immune cells per μl in said test CSF sample obtained from said subject; iii) a level of NKT cells in said test CSF sample obtained from said subject; iv) a level of monocytes in said test CSF sample obtained from said subject, and v) a level of CD56dimCD16+NK cells in a test peripheral blood (PB) sample obtained from said subject, and b) stratifying said subject as suffering from neuro-inflammatory autoimmune diseases, if the following are fulfilled: i) the level of B cells is increased relative to corresponding levels of B cells in control CSF samples obtained from subjects not suffering from neuro-inflammatory autoimmune diseases; ii) the level of immune cells per μl is increased relative to corresponding levels of immune cells per μl in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iii) the level of NKT cells is decreased relative to corresponding levels of NKT cells in said control CSF samples obtained from said subjects not suffering from neuro- inflammatory autoimmune diseases; iv) the level of monocytes is decreased relative to corresponding levels of monocytes in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; v) the level of CD56dimCD16+NK cells is decreased relative to corresponding levels of CD56dimCD16+ NK cells in control PB samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases, wherein the combination of said levels i) - v) of step b) is indicative for whether said subject is suspected to suffer from neuro-inflammatory autoimmune diseases or from another neurological or psychiatric disease manifestation other than neuro-inflammatory autoimmune disease. Further, the present invention relates to a data processing system comprising a processor configured to perform the method of the invention, a flow cytometry device capable of detecting the abovementioned levels and a computer program comprising instructions to cause the data processing system or the flow cytometry device to execute the steps of the method of the invention. Finally, the present invention relates to a kit comprising a fluorescently labeled binding partner for certain surface markers used in the method of the invention.
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (Germany)
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (Canada)
ISTITUTO SUPERIORE DI SANITÀ (Italy)
CONSIGLIO NAZIONALE DELLE RICERCHE (Italy)
IRBM S.P.A. (Italy)
Inventor
Martino, Gianvito
Panina, Paola
Nait-Oumesmar, Brahim
Baron-Van Evercooren, Anne
Kuhlmann, Tanja
Baranzini, Sergio
Goebels, Norbert
Zipp, Frauke
Hanuscheck, Nicholas
Antel, Jack
Agresti, Cristina
Abbracchio, Maria Pia
Eberini, Ivano
Parravicini, Chiara
Olla, Stefania
Bresciani, Alberto
Abstract
The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. Said compounds have been identified through methods of pharmacological screening on a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
28.
RAPID AND DETERMINISTIC GENERATION OF MICROGLIA FROM HUMAN PLURIPOTENT STEM CELLS
The present invention relates to a method for the production of microglia from stem cells comprising the steps of a) targeted insertion of a nucleotide sequence encoding a transcriptional regulator protein into a first genomic safe harbour site; and b) targeted insertion of the coding sequence of the transcription factor PU.1 (SEQ ID NO: 1) into a second genomic safe harbour site, wherein the gene is operably linked to an inducible promoter, which is regulated by the transcriptional regulator protein; expression of PU.1 (SEQ ID NO: 2); and culturing the stem cells received from steps a) and b) with exposure to at least one growth factor or small molecule that mimics signaling during at least one stage of embryonic development of microglia or adult microglia proliferation, differentiation or polarization. Further, the present invention relates to the microglia obtained by the methods of the present invention and various uses thereof.
The present invention relates to a method of generating a nanoparticle comprising (c) contacting an antibody with a composition comprising a first conjugate (A), the first conjugate comprising a positively charged polypeptide conjugated to a bifunctional linker, characterized in that the composition is essentially free of unconjugated bifunctional linker, thereby obtaining a second conjugate (B), the second conjugate comprising the positively charged polypeptide, the bifunctional linker, and the antibody; and (d) contacting the second conjugate (B), a positively charged polypeptide, and a negatively charged molecule, thereby forming a nanoparticle. The present invention also relates to a nanoparticle obtainable by a method of the invention, as well as to a nanoparticle comprising (a) a positively charged polypeptide; (b) a second conjugate (B), the second conjugate comprising an antibody conjugated to a positively charged polypeptide; (c) one or more negatively charged molecules. The present invention also relates to a composition comprising a nanoparticle of the invention and to a nanoparticle or composition of the invention for use in therapy.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
30.
Multi-layer electrolyte assembly for lithium batteries
The invention relates to an electrolyte arrangement for a cell having at least one anode (1) and at least one cathode (3) comprising at least three superposed layers (2.1, 2.2, 2.3), wherein the middle layer (2.2) comprises a porous electrically nonconductive structure, and wherein a layer of a polymer-based electrolyte (2.1, 2.3) is arranged on both opposite sides of the porous electrically nonconductive structure, wherein at least one of the superposed layers (2.1, 2.2, 2.3) contains a ceramic material, wherein the ceramic material of the middle layer (2.2) is selected from metal ion-conductive ceramic material, a ceramic material which does not conduct metal ions, and/or mixtures thereof, and the ceramic material of the polymer-based electrolyte layer(s) (2.1, 2.3) is a metal ion-conductive ceramic material.
H01M 50/451 - Separators, membranes or diaphragms characterised by the material having a layered structure comprising layers of only organic material and layers containing inorganic material
H01M 50/457 - Separators, membranes or diaphragms characterised by the material having a layered structure comprising three or more layers
H01M 50/489 - Separators, membranes, diaphragms or spacing elements inside the cells, characterised by their physical properties, e.g. swelling degree, hydrophilicity or shut down properties
31.
PHOTOSYNTHETIC MICROALGAE AND USE THEREOF FOR HYDROGEN PRODUCTION
The present invention is in the field of molecular hydrogen (Hi) bio-production, particularly, the present invention provides genetically modified photo synthetic microalgae producing hydrogen in complete growth medium under ambient, continuous growth conditions at cost-effective amounts and to a process for hydrogen production using genetically modified photosynthetic microalga.
The present invention relates to a method of identifying a modulator of CatSper channel activity, comprising the steps of: a) contacting a sperm sample with a test solution that is essentially free of free calcium and a test compound; b) detecting the motility of each sperm cell in the sample under the test condition of step (a); c) identifying the test compound as a modulator of CatSper channel activity if the presence of the compound is correlated with an altered motility of the sperm cell relative to the motility of the sperm cell in the test solution without the test compound.
The invention relates to an optical matrix multiplication unit (12) for an optoelectronic system for forming an artificial neural network, having N input waveguides (14), M output waveguides (16) and a plurality of matrix multiplication unit cells (10) for signal processing of optical signals of one each of the N input waveguides (14) and for transferring the processed signals into one each of the M output waveguides (16), wherein each of the matrix multiplication unit cells (10) is allocated to one of the input waveguides (14) and one of the output waveguides (16) and undertakes a unique allocation between said two allocated waveguides (14, 16). According to the invention, each of the matrix multiplication unit cells (10) has, for signal processing and signal transfer, a directional coupler (24), having an electrooptical modulator (26) for transmission control of the directional coupler (24), interconnected between the allocated input waveguide (14) and the allocated output waveguide (16). The invention furthermore relates to a corresponding matrix multiplication unit cell (10) for such an optical matrix multiplication unit (12) and to a corresponding optoelectronic system (44) for forming an artificial neuronal network.
Device for optically determining at least one property of a sample (2) positioned in or on a sample carrier (1) which can be moved relatively to the device, wherein the device is adapted to optically determine in a first step at least one property of a first sample (2) and at least one property of a second sample (2) without relative movement between the device and the sample carrier (1), wherein the sample carrier (1) is adapted to be moved so that in a second step a property of the second sample (2) can be optically determined, wherein the device is adapted to be tuned, depending on the information obtained with regard to the property of the second sample (2) determined in the first step, to optically determine the property of the second sample (2) in the second step, wherein a property of a third sample (2), not optically determined in the first step, is optically determined without relative movement between the device and the sample carrier (1) in the second step such that the device is adapted to be tuned, depending on the information obtained with regard to the property of the third sample (2) determined in the second step, to optically determine the property of the third sample (2) in a third step.
The present invention relates to a method of injecting a substance into a cell, comprising using a capillary that is operatively connected with an electric pulse generator and filled with a solution to be injected and applying a single electric pulse or multiple electric pulses to facilitate the penetration of the cell with said capillary, wherein the single electric pulse or multiple electric pulses are applied when penetrating the cell with said capillary. In addition, the present invention concerns a device for a microinjection according to the herein described method. Also encompassed is the use of an electric pulse generator or electric pulse for enabling the penetration of the cell according to the herein described method.
The disclosure relates to a metal electrode or current collector for an energy storage device. The surface of the electrode or the current collector includes multiple blind hole-like recesses spaced apart from each other. The surface structured in this way is coated with a solid polymer electrolyte. The recesses are filled with the solid polymer electrolyte, as well as a primary or secondary energy storage device including the same.
The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to methods comprising self-circularizing of barcoded nucleic acids in order to ligate an off-barcode region with a barcode, wherein after self-circularizing the off- barcode region becomes closer to the barcode allowing for sequencing the off-barcode region with the barcode.
In various embodiments a module for generating an interference pattern for producing a digital holographic image is provided. The module comprises an adaptive lens arrangement configured to receive, from a microscope, an object wave of an intermediate image of a sample to be examined, and to generate an adapted object wave of the intermediate image of the sample by reducing a curvature of the object wave of the intermediate image; a reference input interface configured to receive an optical fiber delivering a reference wave from the coherent light source to the module and an interference arrangement configured to generate an interference pattern to be received by an imaging sensor arrangement, wherein the interference pattern is based on the adapted object wave and the reference wave from a coherent light source; wherein a position of the reference input interface of the module is configured to be adjustable with respect to at least two directions (x-y), wherein at least one of the adjustable directions is in parallel to a propagation direction of the reference wave leaving the optical fiber.
G02B 27/09 - Beam shaping, e.g. changing the cross-sectioned area, not otherwise provided for
G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
40.
COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION
The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase- 1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase- 1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a method for stratifying spermatozoa in a sample obtained from a subject, comprising assaying the spermatozoa for membrane integrity and assaying the spermatozoa for DNA fragmentation. Thereby the spermatozoa stratification method allows an analysis of defined sperm categories and the prediction whether or not the spermatozoa will be functional. Further, a kit is encompassed for performing the method of spermatozoa stratification.
The invention relates to a resonant-tunneling diode (10) comprising an electrically insulating substrate (12), a metal layer (14), and a transition metal oxide layer (16). The metal layer (14) is applied onto the substrate (12), and the transition metal oxide layer (16) is applied onto the metal layer (14). The metal layer (14) and the transition metal oxide layer (16) have an amorphous structure. The invention additionally relates to a method for producing a resonant-tunneling diode (10) comprising an electrically insulating substrate (12), a metal layer (14), and a transition metal oxide layer (16), having the steps of: a) providing the substrate (12), b) coating the provided substrate (12) with the metal layer (14) using a direct sputtering process such that the metal layer (12) has an amorphous structure, and c) coating the metal layer (14) with the transition metal oxide layer (16) using a reactive sputtering process such that the transition metal oxide layer (16) has an amorphous structure.
H01L 47/00 - Bulk negative resistance effect devices, e.g. Gunn-effect devices; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof
The invention relates to a single photon detector device for detecting an optical signal comprising an optical fiber and at least one nanowire, wherein the optical fiber comprises a core area and a cladding area and is designed to conduct the optical signal along an optical axis, wherein, with respect to the optical axis, a first area of the optical fiber is an entrance area for the optical signal and a second area of the optical fiber is a detector area, and wherein the nanowire becomes superconducting at a predetermined temperature and is designed in the superconducting state to generate an output signal as a function of the optical signal. It is provided that in the detector area of the optical fiber the nanowire extends essentially along the optical axis of the optical fiber. A single photon detector device is thus provided which has a simple structure, a high efficiency, a high detection rate and a high spectral bandwidth.
The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase- 1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
47.
COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase- 1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
49.
A CULTURE PLATFORM FOR CULTIVATING TISSUE AND METHOD FOR OBSERVING TISSUE CULTIVATED THEREIN
In various embodiments a culture platform for cultivating tissue is provided, comprising: a first component (2) comprising at least one culture chamber (21) formed therein, the culture chamber (21) comprising a bottom (23), a sidewall and an open top (22); and a second component (2) comprising a base (31) and at least one pair of posts (32) extending from the base (31); wherein the first component (2) and the second component (3) are sized and configured to be mated with one another such that when the second component (3) is placed on the first component (2), the at least one pair of posts (32) is inserted into the at least one culture chamber (21). Furthermore, a method for observing tissue cultivated therein is provided.
In various embodiments a culture platform for cultivating tissue is provided, comprising: a first component (2) comprising at least one culture chamber (21) formed therein, the culture chamber (21) comprising a bottom (23), a sidewall and an open top (22); and a second component (2) comprising a base (31) and at least one pair of posts (32) extending from the base (31); wherein the first component (2) and the second component (3) are sized and configured to be mated with one another such that when the second component (3) is placed on the first component (2), the at least one pair of posts (32) is inserted into the at least one culture chamber (21). Furthermore, a method for observing tissue cultivated therein is provided.
The invention relates to an electrochemical cell composed of an electrode having a relatively low redox potential and an electrode having a relatively high redox potential relative to a reference electrode system M│M+ and an electrolyte, wherein the electrode having the relatively low redox potential comprises an electrode with sulfur as the active material and the electrode having the relatively high redox potential comprises an electrode with an anion-absorbing active material; wherein charging/discharging comprises intercalation and deintercalation of both the cations of the electrolyte into the electrode having the relatively low redox potential and the anions into the electrode having the relatively high redox potential. The present invention further relates to the use of the electrochemical cell according to the invention in an alkali metal-, alkaline earth metal-, aluminium- or zinc-based energy storage means based on the dual-ion mechanism.
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
52.
Process for synthesizing fluorinated cyclic aliphatic compounds
The present invention relates to a novel method for producing fluorinated cycloaliphatic compounds from the analogous aromatic compounds by hydrogenation with an Rh-carbene catalyst system.
C07C 17/354 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules by hydrogenation
C07C 41/20 - Preparation of ethers by reactions not forming ether-oxygen bonds by hydrogenation of carbon-to-carbon double or triple bonds
C07C 67/303 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 211/76 - Oxygen atoms attached in position 2 or 6
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
System (1) comprising a stand device (2), in particular a gynecological stand device, and a fixation device (3) configured to receive and hold an object, in particular an animal, to be investigated in position, wherein the stand device (3) comprises a housing (4) provided with a lightning device (7), and wherein the fixation device (3) is releasable attached to the stand device (2) in a position in which light of the lightning device illuminates an area of the object to be investigated received in the fixation device (3), in particular a genital tract of an animal.
The present invention relates to an optically switchable adhesive comprising one or more arylazo-3,5-dimethylisoxazole derivatives according to the following formula I: (I) where groups R1to R3are independently selected from the group consisting of H, F, Cl, Br, I and alkoxy or ester groups having an unsubstituted or part-fluorinated or perfluorinated, branched or unbranched C2-C20 alkyl chain, where at least one of the groups R1to R3is an alkoxy or ester group; the groups R4– R5 are independently selected from the group consisting of H, C1-C3 alkyl and halogenated C1-C3 alkyl; and the groups X and X' are independently selected from the group consisting of H, F, Cl, Br and I. The present invention further relates to a method of reversible, optically switchable joining of workpieces, and to the use of the optical adhesives of the invention for reversible joining of workpieces.
C09J 5/06 - Adhesive processes in generalAdhesive processes not provided for elsewhere, e.g. relating to primers involving heating of the applied adhesive
For a single photon detector device for detecting an optical signal, the aim is to provide a solution which makes it possible to provide efficient single photon detectors having a very high time resolution, by using high-temperature superconductors which can operate at readily achievable cooling temperatures, and which also permit the simple production of a waveguide structure for use with high-temperature superconductors. To achieve this aim, a single photon detector device for detecting an optical signal is proposed, comprising a lattice-matched substrate (2), at least one lattice-matched waveguide (3), wherein the lattice-matched waveguide (3) is diffused, by means of metal ions, into the lattice-matched substrate (2) in an area of the lattice-matched substrate (2) close to the surface, and at least one superconducting nanowire (4), wherein the superconducting nanowire (4) is applied to the lattice-matched waveguide (3) and is composed of a high-temperature superconductor. Also disclosed are a method for producing a single photon detector device (1), a system having a single photon detector device (1) and the use of a single photon detector device (1) in a photonic chip.
n42042020) alkylene group. The liposomes have an average diameter of 65 to 1000 nm. Furthermore, the present invention is directed to the use of the liposome-based carrier system for use in medicine, in particular for use in treating or preventing of peeling skin syndromes (PSS), the Netherton Syndrome, SAM Syndrome psoriasis vulgaris, atopic dermatitis, impetigo, microbial eczema, microbial eczema associated with dermatomycosis, NISCH Syndrome, androgenetic alopecia, alopecia areata, bullous immunodermatoses, and epidermolysis bullosa, skin tightening, and dry skin conditions. Moreover, the invention is directed to pharmaceutical compositions comprising the liposome- based carrier system
Method for assessing the suitability of a sperm for fertilization of an oocyte based on longitudinal axis rotation In various embodiments a method for assessing the suitability of a sperm for fertilization of an oocyte is provided, the method comprising measuring the rotation of at least one sperm in a sperm sample around its longitudinal axis, the sperm being obtained from a male subject, wherein observing no rotation of the sperm is indicative that the sperm is not suitable for fertilization of an oocyte; whereas observing rotation indicates that the sperm may be suitable for fertilization.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
58.
METHOD FOR ESTABLISHING AN INDIVIDUAL PHYSICAL ACTIVITY PROGRAM FOR A SUBJECT FOR REDUCING AN INDIVIDUAL RISK OF THE SUBJECT FOR DEVELOPING A CARDIOVASCULAR DISEASE
The present invention relates to a method for establishing an individual physical activity program for a subject for reducing an individual risk of the subject for developing a cardiovascular disease, comprising the following steps: (i) determining the concentration of at least one circulating miRNA in at least one fluid sample obtained from the subject, at least before and after the subject has conducted physical activity; wherein the at least one circulating miRNA is selected from certain miRNAs; (ii) comparing the in step (i) determined concentration(s), wherein the result of this comparison is indicative of whether said subject has an individual risk for developing a cardiovascular disease under certain conditions; and (iii) establishing the individual physical activity program for the subject based on the result of step (ii). The present invention further relates to various uses of miRNAs in any of the methods according to the present invention.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention relates to an isolated polypeptide or to a composition of isolated polypeptides comprising (a) at least one first intein amino acid sequence (a1) and at least one first extein amino acid sequence (a2); wherein the at least one first intein amino acid sequence is an N-terminal sequence of a split intein or fragment thereof; wherein the at least one first extein sequence is fused to the N-terminus of the at least one first intein sequence and has a length of at least 1; and (b) at least one second intein amino acid sequence (b1) and at least one second extein sequence (b2); wherein the at least one second intein sequence is a C-terminal sequence of a split intein or fragment thereof; wherein the at least one second extein sequence is fused to the C-terminus of the at least one second intein sequence and has a length of at least 1; wherein the catalytic motifs of the at least one first intein amino acid sequence and/or of the at least one second intein amino acid sequence are free of cysteine residues; wherein the first and second intein amino acid sequence specifically interact with each other. Additionally, the invention relates to at least one isolated nucleic acid molecule comprising at least one nucleotide sequence encoding an isolated polypeptide according to the invention or a homolog, variant or complement thereof. Finally, the invention pertains to a method for modifying amino acid sequences or to a use of said isolated polypeptide(s) or said at least one isolated nucleic acid molecule.
In an optical device for bidirectional coupling of a waveguide (7) to an external medium (6), the aim of the invention is to widen the coupling bandwidth of the optical device, so that a wide spectrum of wavelengths can be coupled into an external medium via the optical device. This aim is achieved in that the optical device comprises at least one taper structure (2), the taper structure (2) comprising a beam entry segment (3), the beam entry segment (3) being designed so as to couple a light beam (5) from the waveguide (7) into the taper structure (2), and the taper structure comprising a beam exit segment (4), the beam exit segment (4) being designed so as to focus the light beam (5) and to couple same into the external medium (6), the taper structure (2) comprising at least one first reflective surface (8) between the beam entry segment (3) and the beam exit segment (4), and the first reflective surface (8) being designed so as to deflect the light beam (5) out of the plane of the waveguide (7).
The present invention relates to a method for the production of microglia from stem cells comprising the steps of a) targeted insertion of a nucleotide sequence encoding a transcriptional regulator protein into a first genomic safe harbour site; and b) targeted insertion of the coding sequence of the transcription factor PU.1 (SEQ ID NO: 1) into a second genomic safe harbour site, wherein the gene is operably linked to an inducible promoter, which is regulated by the transcriptional regulator protein; expression of PU.1 (SEQ ID NO: 2); and culturing the stem cells received from steps a) and b) with exposure to at least one growth factor or small molecule that mimics signaling during at least one stage of embryonic development of microglia or adult microglia proliferation, differentiation or polarization. Further, the present invention relates to the microglia obtained by the methods of the present invention and various uses thereof.
The present invention relates to a method for the production of microglia from stem cells comprising the steps of a) targeted insertion of a nucleotide sequence encoding a transcriptional regulator protein into a first genomic safe harbour site; and b) targeted insertion of the coding sequence of the transcription factor PU.1 (SEQ ID NO: 1) into a second genomic safe harbour site, wherein the gene is operably linked to an inducible promoter, which is regulated by the transcriptional regulator protein; expression of PU.1 (SEQ ID NO: 2); and culturing the stem cells received from steps a) and b) with exposure to at least one growth factor or small molecule that mimics signaling during at least one stage of embryonic development of microglia or adult microglia proliferation, differentiation or polarization. Further, the present invention relates to the microglia obtained by the methods of the present invention and various uses thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
The present invention relates to an in vitro method for determining or diagnosing infertility of a male subject comprising the steps of (a) contacting a sperm sample obtained from said subject with a calcium-free test solution, (b) detecting the motility of the sperm in said sample under the test condition of step (a), and (c) determining infertility of the male subject based on the motility detected in step (b). Further, the present invention relates to a kit for use in a method for determining or diagnosing infertility of a male subject comprising (a) a calcium-free test solution, and (b) a calcium-containing control solution.
The invention relates to an electrolyte assembly for a cell with at least one anode (1) and at least one cathode (3), comprising at least three layers (2.1, 2.2, 2.3) lying on top of one another, wherein the middle layer (2.2) has a porous electrically non-conductive structure, and wherein a layer of a polymer-based electrolyte (2.1, 2.3) is arranged on both opposing sides of the porous electrically non-conductive structure, wherein at least one of the layers (2.1, 2.2, 2.3) lying on top of one another contains a ceramic material, wherein the ceramic material of the middle layer (2.2) is selected from metal-ion-conducting ceramic material, a ceramic material that does not conduct metal ions, and/or mixtures thereof, and the ceramic material of the polymer-based electrolyte layer/s (2.1, 2.3) is a metal-ion-conducting ceramic material.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The invention relates to a single-photon detector (10) for detecting an optical signal, comprising an optical fiber (12) and at least one nanowire (24). The optical fiber (12) has a core region (14) and a cladding region (16) and is designed to guide the optical signal along an optical axis (18). A first region of the optical fiber, with respect to the optical axis (18), is an input region (20) for the optical signal, and a second region of the optical fiber is a detector region (22). The nanowire (24) becomes superconductive at a specified temperature and in the superconductive state is designed to generate an output signal on the basis of the optical signal. In the detector region (22) of the optical fiber (12), the nanowire (24) extends substantially along the optical axis (18) of the optical fiber (12). Thus, a single-photon detector is provided which has a simple construction, a high degree of efficiency, a high detection rate, and a wide spectral bandwidth.
The invention relates to a metal electrode or current collector for an energy store, wherein the surface of the electrode or of the power collector comprises a plurality of blind hole-like recesses, which are spaced apart from each other, the surface structured in this way being coated with a solid polymer electrolyte, the recesses being filled with the solid polymer electrolyte. The invention further relates to a primary or secondary energy store comprising same.
The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives.
H01M 10/0567 - Liquid materials characterised by the additives
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 10/0569 - Liquid materials characterised by the solvents
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
C07D 273/01 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having one nitrogen atom
69.
POLYMER-PARTICLE LIGHT-CLEAVABLE CARRIER SYSTEMS FOR PHOTODYNAMIC THERAPY
The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C08G 64/30 - General preparatory processes using carbonates
C08G 63/682 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing halogens
C08G 63/688 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing sulfur
C08G 64/16 - Aliphatic-aromatic or araliphatic polycarbonates
C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
The present invention relates to a method of diagnosing a subject with multiple sclerosis comprising determining different cell ratios in a test cerebrospinal fluid (CSF) sample obtained from said subject, wherein the combination of said specific cell ratios is indicative for whether or not said subject suffers from multiple sclerosis. Further, the present invention relates to a data processing system comprising a processor configured to perform the steps of said method above, a flow cytometry device capable of detecting the specific cell levels in a test CSF sample comprising the defined data processing system, a computer program comprising instructions to cause the data processing system or the flow cytometry device to execute the steps of the defined method, as well as a computer-readable medium having stored thereon the computer program as defined. The present invention also relates to a kit and an agent for use in the treatment of multiple sclerosis.
The present invention relates to a process for the preparation of a non-random chitosan polymer and a non-random chitosan polymer obtainable by said process.
The present invention relates to a method of stratifying a subject having no symptoms of acute tonsillitis for tonsillectomy or tonsillotomy, to a method of diagnosing recurrent tonsillitis in a subject having no symptoms of acute tonsillitis and to a method of predicting the risk or the predisposition for recurrence of acute tonsillitis (RAT) in a subject having no symptoms of acute tonsillitis. These methods are based on the determination of the biomarkers IL-1 β, IL-18 and S100A8/S100A9 in said subject.
The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-κB-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-κB-associated postnatal inflammatory disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
75.
METHOD FOR INCREASING THE YIELD OF OXIDOSQUALENE, TRITERPENES AND/OR TRITERPENOIDS AND HOST CELL THEREFORE
The present invention relates to a method of increasing the yield of at least one of oxidosqualene, triterpenes and/or triterpenoids in a specifically engineered host cell and a respective host cell as well as to the use of said host cell for manufacturing the at least one of oxidosqualene, triterpenes and/or triterpenoids.
The present invention relates to a method of increasing the yield of at least one of oxidosqualene, triterpenes and/or triterpenoids in a specifically engineered host cell and a respective host cell as well as to the use of said host cell for manufacturing the at least one of oxidosqualene, triterpenes and/or triterpenoids.
The present invention relates to an ergosterol-biosynthesis inhibitor for use in a method of treatment or prophylaxis of an influenza virus infection in a subject. The ergosterol-biosynthesis inhibitor is a compound comprising at least one 1/-/-1,2,4-triazole-1-yl group and is selected from the group consisting of itraconazole, posaconazole, voriconazole, fluconazole or fosfluconazole.
The invention relates to a novel method for producing fluorinated heterocyclic aliphatic compounds from the analogous aromatic compounds by hydrogenating with an Rh-catalyst system.
C07D 211/72 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
C07F 7/08 - Compounds having one or more C—Si linkages
79.
PROCESS FOR SYNTHESIZING FLUORINATED CYCLIC ALIPHATIC COMPOUNDS
The invention relates to a novel method for producing fluorinated cyclic aliphatic compounds from the analogous aromatic compounds by hydrogenating with an Rh-catalyst system.
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
The present invention relates to the use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds. The present invention further relates to a method for treating wounds, comprising rinsing the wound with a wound solution and treating the wound with cold atmospheric plasma.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
The invention relates to a system and to a method for producing wavelength-tunable laser output pulses using parametric processes, wherein a time overlap between pump pulses and seed pulses in a parametric amplification medium is ensured by means of a simultaneous and coordinated detuning of the pump pulse wavelength and of the pump pulse repetition rate. On the basis of this parameter coupling, lasers having a widely tunable wavelength range can be obtained, which lasers can be completely fiber-based and are also suitable for modern nonlinear microscopy or fluorescence microscopy by virtue of particularly quick response behavior.
The invention relates to a method for producing ferroelectric domains in a ferroelectric crystal. To create domains that are as narrow and long as possible, according to the invention the crystal is moved in the direction of the optical axis (z axis) to expose it to a series of focused laser pulses, which induce a (relatively short) filament in the direction of the optical axis (z axis). After moving the crystal transversely (x or y direction), further short filaments are additionally created. During or after the laser treatment, the crystal is heated and subsequently cooled, whereby the desired (relatively long) domains are produced under the short filaments.
The present invention relates to an aqueous polymer electrolyte comprising: a) water in a range of ≥ 5 wt% to ≤ 95 wt%, b) a metal ion component comprising a metal cation selected from the group consisting of Li+, Na+, K+, Mg2+, Al3+, Ca2+, Fe2+, Fe3+and Zn2+, and c) a polymer component comprising repeat units according to the following formula (I) : -[C(X1)(X2)-C(Y1)(Y2)-Z]- wherein: X1, X23226922; Y1, Y234622, -COOH, -COO-61022O-61022OH; Z is an optional element selected from the group consisting of -O-, -CH2~, -CO- and methyl cellulose; wherein the metal ion component and the polymer component together amount to a content range of ≥ 5 wt% to ≤ 95 wt%, all wt% referring to a total amount of the aqueous polymer electrolyte of 100 wt%.
The invention relates to an electrolyte for an energy store comprising a conducting salt and a solvent, characterized in that the solvent comprises at least one compound according to the general formula (1), as indicated in the following: wherein R1, R2, R3, R4 are, identically or independently of each other, selected from the group comprising linear or branched C1-6-alkyl, C2-6-alkenyl, C2-6-alkinyl, C3-6-cycloalkyl and/or phenyl, each unsubstituted or mono- or polysubstituted by a substituent selected from the group comprising F, CN and/or C1-2-alkyl, mono- or polysubstituted with fluorine.
The invention relates to an electrode material, comprising N-substituted poly(vinylphenothiazine) or poly(vinylphenoxazine) in a range from ≥ 20 wt% to ≤ 80 wt%, carbon particles in a range from ≥ 10 wt% to ≤ 70 wt%, and binder in a range from ≥ 0 wt% to ≤ 10 wt%, the specifications relating to a total weight of the components of 100 wt%. The invention further relats to a method for producing a composite electrode using the material.
H01M 4/137 - Electrodes based on electro-active polymers
H01G 11/06 - Hybrid capacitors with one of the electrodes allowing ions to be reversibly doped thereinto, e.g. lithium ion capacitors [LIC]
H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/02 - Electrodes composed of, or comprising, active material
88.
PROCESS FOR SYNTHESIZING FLUORINATED CYCLIC ALIPHATIC COMPOUNDS
The invention relates to a new type of process for synthesizing fluorinated cyclic aliphatic compounds from the analogous aromatic compounds by means of hydrogenation with an Rh-carbene catalyst system.
C07C 17/354 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules by hydrogenation
C07C 23/10 - Monocyclic halogenated hydrocarbons with a six-membered ring
C07C 69/75 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of acids with a six-membered ring
89.
ELECTROLYTE-ADDITIVE FOR LITHIUM-ION BATTERY SYSTEMS
The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives.
The invention relates to an electrolyte for an electrochemical energy storage means comprising an electrolyte salt and at least one solvent, wherein the solvent comprises in the range from ᡶ 50% by weight to ឬ 100% by weight, based on the total weight of the solvent, of a nonaromatic cyclic nitrile of the formula (1) NC-R1 or of a mixture of the cyclic nitrile of the formula (1) NC-R1 and a linear nitrile of the formula (2) NC-R2, in which: R1 is selected from the group comprising C3-C7-cycloalkyl and/or C3-C7-cycloalkenyl, each unsubstituted or mono- or polysubstituted by at least one substituent selected from the group comprising F, C1-C5-alkyl, C1-C4-alkoxy and/or C1-C4-siloxy, each unsubstituted or mono- or polysubstituted by fluorine, R2 is selected from the group comprising alkoxyalkyl, siloxyalkyl, where the alkyl group in each case has 1 to 8 carbon atoms and the alkoxy and siloxy groups each have 1 to 4 carbon atoms and unsubstituted or mono- or polysubstituted by fluorine, and/or unsubstituted or mono- or poly-fluorine-substituted C1-C8-alkyl.
The present invention relates to a method for producing astrocytes. Furthermore, the invention relates to an astrocyte obtainable by a method of the present invention. In addition, the present invention relates to a pharmaceutical composition. Also encompassed are astrocytes of the present invention for use in therapy and for use in a method of treating a disease. The present invention also relates to a method for identifying agents, which modulate astrocyte viability or function as well as a kit.
The invention relates to a a device for generating output laser pulses having a tunable central wavelength (1), on the basis of a parametric amplification. The aim of the invention is to provide a laser system, which has reduced complexity yet has great ability to tune the wavelength, enables fast switching of the wavelength, and allows the spectral bandwidth of the emitted pulses to be set. This aim is achieved in that an optical apparatus (4) is provided in order to be able to adjust the bandwidth of the output laser pulses, which optical apparatus is designed to influence the spectral phase of the pump pulses in accordance with the spectral phase of the seed pulses. The output laser pulses can be provided by a Q-switched laser diode (3), and the energy thereof can be increased by means of a Yb-doped fiber amplifier (7). The OPO (2) can consist of a fiber ring containing a single-mode fiber (5) for providing the desired dispersion, and the parametric amplification can occur in a photonic crystal fiber (6).
H01S 3/23 - Arrangement of two or more lasers not provided for in groups , e.g. tandem arrangement of separate active media
H01S 5/062 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium by varying the potential of the electrodes
Disclosed is a protective cap (400) for an imaging device, the cap having a hollow protective cap body with a front end (404), a cylindrical surface (402) and an open rear end (406), through which the imaging device can be inserted into the protective cap, and a depression (408) provided in the front end. The protective cap also has at least one channel (502) provided at the front part of the protective cap body, beneath the front end, the at least one channel having a first opening that is provided in the lateral wall (412) of the depression and a second opening that is provided preferably in the cylindrical surface of the protective cap body.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
A61B 1/24 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressorsInstruments for opening or keeping open the mouth
94.
S100A8/S100A9-INDUCED IMMUNOTOLERANCE IN NEWBORN SUBJECTS
The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subjectfor developing a NF-?B-associated postnatal inflammatory disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
95.
S100A8/S100A9-INDUCED IMMUNOTOLERANCE IN NEWBORN SUBJECTS
The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-κB-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subjectfor developing a NF-κB-associated postnatal inflammatory disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention relates to a polypeptide capable of specifically inhibiting human adenylyl cyclase (5) wherein said polypeptide does essentially not inhibit human adenylyl cyclase (6). The present invention also relates to the polypeptide for use in specifically inhibiting human adenylyl cyclase (5) in a subject. The present invention further relates to an in vitro use of the polypeptide for inhibiting human adenylyl cyclase (5) and an in vitro method for inhibiting human adenylyl cyclase (5).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
97.
COMPLEX-SPECIFIC STANDARDIZATION OF IMMUNOLOGICAL METHODS FOR THE QUANTIFICATION OF S100A12
The present invention relates to mutants of S100A12 having at least one mutation in the high-affinity calcium binding hand or the low-affinity calcium binding hand or the zinc binding region. The present invention also relates to methods of detecting S100A12 dimers in a sample as well as methods of diagnosis using the S100A12 mutant of the invention, as well as to diagnostic compositions and kits comprising such an S100A12 mutant. The present invention further relates to a method of generating an antibody that specifically binds to an S100A12 dimer using the S100A12 mutant of the invention, as well as to an antibody that specifically binds to an S100A12 dimer.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
98.
MEANS AND METHODS FOR THE GENERATION OF OLIGODENDROCYTES
The present invention relates to methods of generating oligodendroglial lineage cells from human cells selected from the group consisting of neural progenitor cells (NPCs), pluripotent stem cells (PSCs), induced pluripotent stem cells (iPSCs) and fibroblasts. The invention furthers relates to methods of screening for a compound promoting oligodendroglial differentiation and/or maturation, specifically to high throughput methods. In addition, the invention relates to cells obtainable by these methods and use of these cells in therapy.
The invention relates to the use of an electrolyte containing a metal compound of the formula M(OSiR3)x and/or LiAl(OSiR3)4, wherein x is 2, 3, or 4 and M is selected from the group comprising Mg2+, Αl3+, and/or Ti4+, to produce a solid electrolyte interphase (CEI) on the cathode of a lithium-based electrochemical energy store.
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
The present invention relates to a method of preparing an oligosaccharide composition, said method comprising the steps of: (a)providing a pectin; and (b)performing, in any order, conversion of carboxylic acid groups to the corresponding alcohols and cleavage of glycosidic bonds under conditions suitable to give an oligosaccharide composition. The present invention also relates to an oligosaccharide composition obtainable or being obtained by using such a method of preparing an oligosaccharide composition. The present invention further relates to a method of preparing a coupling product of an oligosaccharide composition. The present invention is also directed to a coupling product of an oligosaccharide composition. The present invention also relates to pharmaceutical compositions comprising the oligosaccharide composition or the coupling product of an oligosaccharide composition as well as medical uses and diagnostic uses.
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
patents
